Cresco Labs Inc. (OTCMKTS:CRLBF) Receives Consensus Recommendation of “Buy” from Analysts

Cresco Labs Inc. (OTCMKTS:CRLBFGet Rating) has earned an average rating of “Buy” from the eight analysts that are presently covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $21.67.

Several analysts have issued reports on CRLBF shares. Piper Sandler dropped their price objective on Cresco Labs from $14.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, March 24th. Atb Cap Markets reiterated an “outperform” rating on shares of Cresco Labs in a research note on Wednesday, March 23rd. Finally, Canaccord Genuity Group lowered their target price on Cresco Labs from C$15.00 to C$12.00 in a research note on Friday, March 25th.

OTCMKTS:CRLBF opened at $5.38 on Monday. The stock’s 50 day moving average price is $6.31 and its two-hundred day moving average price is $7.12. Cresco Labs has a 12-month low of $5.16 and a 12-month high of $13.65.

About Cresco Labs (Get Rating)

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand, as well as cannabis products under the Reserve brand.

Further Reading

Analyst Recommendations for Cresco Labs (OTCMKTS:CRLBF)

Receive News & Ratings for Cresco Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cresco Labs and related companies with MarketBeat.com's FREE daily email newsletter.